Loading stock data…
$2.96-0.02 (-0.55%)
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States.
Artelo Biosciences, Inc. in the Healthcare sector is trading at $2.96 with a market capitalization of $3M. The stock is currently near its 52-week low of $2.92, remaining 87.6% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 0 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.50M↑ | -$2.69M↑ | -$2.79M↑ | -$3.09M↑ | -$3.15M |
| Net Income | -$2.43M↑ | -$2.96M↑ | -$4.17M↓ | -$3.12M↑ | -$3.22M |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual can...